StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 16:26:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form S-8 Curanex Pharmaceuticals http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Curanex+Pharmaceuticals++++++++++++++/26795977.html si-local-file:///var/storage/secattach/20260721/26795977.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Curanex+Pharmaceuticals++++++++++++++/26795977.html Tue, 21 Jul 2026 16:26:00 -0400 CURX O.48073990 Form S-8 Curanex Pharmaceuticals http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Curanex+Pharmaceuticals++++++++++++++/26795977.html si-local-file:///var/storage/secattach/20260721/26795977.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Curanex+Pharmaceuticals++++++++++++++/26795977.html Tue, 21 Jul 2026 16:26:00 -0400 CURX O.48073990 Form DEF 14C Curanex Pharmaceuticals For: Jun 29 http://www.streetinsider.com/SEC+Filings/Form++DEF+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+29/26703618.html si-local-file:///var/storage/secattach/20260629/26703618.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+29/26703618.html Mon, 29 Jun 2026 10:19:00 -0400 CURX O.48073990 Form DEF 14C Curanex Pharmaceuticals For: Jun 29 http://www.streetinsider.com/SEC+Filings/Form++DEF+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+29/26703618.html si-local-file:///var/storage/secattach/20260629/26703618.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+29/26703618.html Mon, 29 Jun 2026 10:19:00 -0400 CURX O.48073990 Form PRE 14C Curanex Pharmaceuticals For: Jun 18 http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html si-local-file:///var/storage/secattach/20260618/26667217.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html Thu, 18 Jun 2026 17:12:00 -0400 CURX O.48073990 Form PRE 14C Curanex Pharmaceuticals For: Jun 18 http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html si-local-file:///var/storage/secattach/20260618/26667217.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html Thu, 18 Jun 2026 17:12:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 14 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html si-local-file:///var/storage/secattach/20260514/26491326.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html Thu, 14 May 2026 09:16:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 14 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html si-local-file:///var/storage/secattach/20260514/26491326.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html Thu, 14 May 2026 09:16:00 -0400 CURX O.48073990 Curanex completes manufacturing milestones for Phyto-N drug candidate http://www.streetinsider.com/Corporate+News/Curanex+completes+manufacturing+milestones+for+Phyto-N+drug+candidate/26490907.html <p>Curanex Pharmaceuticals Inc. (NASDAQ: CURX) reported progress on its lead drug candidate Phyto-N during the first quarter of 2026, completing manufacturing and toxicology studies ahead of a planned FDA submission.</p><p>The company completed production of a Good Manufacturing Practice-compliant pilot-scale batch of Phyto-N in February 2026. The material will support toxicology and pharmacokinetic studies required for an Investigational New Drug application planned for the fourth quarter of 2026.</p><p>In March 2026, Curanex completed a 28-day toxicology study of Phyto-N in rats and dogs. The company reported no treatment-related adverse findings at any dose level in either species, including at the maximum feasible http://www.streetinsider.com/Corporate+News/Curanex+completes+manufacturing+milestones+for+Phyto-N+drug+candidate/26490907.html Thu, 14 May 2026 08:55:21 -0400 CURX Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Form 10-Q Curanex Pharmaceuticals For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html si-local-file:///var/storage/secattach/20260514/26490826.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html Thu, 14 May 2026 08:48:00 -0400 CURX O.48073990 Form 10-Q Curanex Pharmaceuticals For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html si-local-file:///var/storage/secattach/20260514/26490826.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html Thu, 14 May 2026 08:48:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html si-local-file:///var/storage/secattach/20260507/26451049.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html Thu, 07 May 2026 11:45:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html si-local-file:///var/storage/secattach/20260507/26451049.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html Thu, 07 May 2026 11:45:00 -0400 CURX O.48073990